endovascular.es

Título: Cook Medical receives FDA approval for the Zenith Alpha™ Thoracic Endovascular Graft
Fecha: 17-09-2015
Bloomington, Ind. ─ Cook Medical has received premarket approval from the U.S. Food and Drug Administration (FDA) for its lower-profile Zenith Alpha™ Thoracic Endovascular Graft. Zenith Alpha Thoracic is indicated for the endovascular treatment of patients with isolated lesions of the descending thoracic aorta (not including dissections) having vascular anatomy suitable for endovascular repair1. The approval of Zenith Alpha Thoracic was based on two pivotal clinical trials that studied the safety and effectiveness of the device in patients with aortic aneurysm/ulcer or blunt traumatic aortic injury.
Zenith Alpha Thoracic will allow physicians to treat more patients with TEVAR (thoracic endovascular aortic repair) because of its lower-profile introduction system and broad range of sizes. With a 16-20 French delivery system, Zenith Alpha Thoracic was developed to address vascular access issues associated with larger-profile devices and to increase conformability in tortuous anatomy.
The device’s introduction system also features an ergonomic design that requires fewer procedural steps than previous designs to deploy the device without sacrificing the precision and control of the Zenith platform.
“Despite all the successes we’ve seen over the past few decades in endovascular aneurysm repair, we continue to be frustrated when we have to put a large sheath through iliac arteries that are smaller than the delivery system,” said Karl Illig, MD, Professor Surgery and director of the division of Vascular Sugary at USF Morsani College of Medicine. “Development, testing, and now approval of the Zenith Alpha Thoracic device is long-awaited in this regard.”
“The approval of Zenith Alpha Thoracic accelerates Cook Medical’s vision to provide physicians with disease-specific treatment options that fit each patient’s unique anatomy and disease state,” said Nicky James, vice president and global business unit leader of Cook Medical’s Aortic Intervention division.
Zenith Alpha Thoracic was first launched in Europe following CE Mark approval in 2013, and is the newest addition to a growing portfolio of clinically proven Zenith endovascular grafts and procedural accessories in the U.S. For more information about Alpha Thoracic and other Aortic Intervention products, visit cookmedical.com/aortic-intervention and follow us on Twitter @CookEVAR.
Dr. Karl Illig is a paid global principal investigator of the Zenith Alpha Thoracic clinical trial.
1 Vascular anatomy suitable for endovascular repair includes nonaneurysmal aortic segments (fixation sites) proximal and distal to the thoracic lesion with a length of at least 20 mm, and with a diameter measured outer wall to outer wall of no greater than 42 mm and no less than 15 mm.
About Cook Medical
Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at www.cookmedical.com, and for the latest news, follow us on Twitter, Facebook and LinkedIn.
Fuente: endovascular.es

endovasculares.es